UBLITUXIMAB

Brand name:

• Briumvi®

Pharmaceutical company:

KIRCHMANN ENTERPRISES PTY LTD

Condition/indication:
(therapeutic use)

• Relapsing-remitting multiple sclerosis (RRMS)

PBAC Submission type:

New PBS listing (Category 2)

Comment:

--

Public Summary Document:

PBAC Public Summary Documents – May 2025

Related medicines:

--

Submission received for:

May 2025 PBAC meeting

Opportunity for consumer comment:

Open 30/01/2025 and close 26/03/2025 (see PBS Website)

PBAC meeting:

Held on 09/05/2025

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

25/06/2025

Lodgement of required documentation:

14/07/2025

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 10/11/2025

Status:

Finalised

7Government processes:

Commenced on 13/11/2025

8Medicine listed on the PBS:

Has not yet occurred

---